Objectives To characterise pregnancy course and outcomes in women with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C).
Methods From a combined Johns Hopkins/Dutch ARVD/C registry, we identified 26 women affected with ARVD/C (by 2010 Task Force Criteria) during 39 singleton pregnancies >13 weeks (1–4 per woman). Cardiac symptoms, treatment and episodes of sustained ventricular arrhythmias (VAs) and heart failure (HF) ≥ Class C were characterised. Obstetric outcomes were ascertained. Incidence of VA and HF were compared with rates in the non-pregnant state. Long-term disease course was compared with 117 childbearing-aged female patients with ARVD/C who had not experienced pregnancy with ARVD/C.
Results Treatment during pregnancy (n=39) included β blockers (n=16), antiarrhythmics (n=6), diuretics (n=3) and implantable cardioverter defibrillators (ICDs) (n=28). In five pregnancies (13%), a single VA occurred, including two ICD-terminated events. Arrhythmias occurred disproportionately in probands without VA history (p=0.045). HF, managed on an outpatient basis, developed in two pregnancies (5%) in women with pre-existing overt biventricular or isolated right ventricular disease. All infants were live-born without major obstetric complications. Caesarean sections (n=11, 28%) had obstetric indications, except one (HF). β Blocker therapy was associated with lower birth weight (3.1±0.48 kg vs 3.7±0.57 kg; p=0.002). During follow-up children remained healthy (median 3.4 years), and mothers were without cardiac mortality or transplant. Neither VA nor HF incidence was significantly increased during pregnancy. ARVD/C course (mean 6.5±5.6 years) did not differ based on pregnancy history.
Conclusions While most pregnancies in patients with ARVD/C were tolerated well, 13% were complicated by VA and 5% by HF.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy, characterised by fibro-fatty replacement of the right ventricular (RV) myocardium, which predisposes patients to ventricular arrhythmias (VAs), RV dysfunction and an increased risk of sudden cardiac death.1 ,2 Patients typically present in their second to fifth decade with symptoms associated with VAs.3 Inheritance of ARVD/C is autosomal dominant with reduced penetrance and marked variable expressivity.4 ,5 Consistent with this, ARVD/C is equally common in men and women, although men have a somewhat worse disease course.3 ,5 Mutations, primarily in genes encoding the cardiac desmosome, can be identified in up to two-thirds of patients.6
Although ARVD/C is frequently diagnosed in childbearing-aged women,6 little is known about pregnancy and ARVD/C. Published data are limited to one small case series and seven isolated case reports7–14 describing a total of 13 pregnancies. Thus, beyond appreciation that there are likely risks associated with the hemodynamic and hormonal changes of pregnancy,15 little disease-specific data exist to guide obstetric care of patients with ARVD/C. Taking advantage of a combined registry of American and Dutch patients with ARVD/C, we therefore developed a study to (1) characterise pregnancy course and outcomes in women with ARVD/C, (2) identify women at highest risk for adverse outcomes during pregnancy and (3) compare overall disease course of childbearing-aged patients who did and did not experience an ARVD/C-affected pregnancy.
The study population was drawn from the Johns Hopkins and Interuniversity Cardiology Institute of the Netherlands ARVD/C registries. Both prospectively follow patients with ARVD/C. As shown in figure 1 and the online supplementary methods, for this study we included female registry enrolees who met diagnostic 2010 Task Force Criteria (TFC)16 while childbearing aged (15–45 years) and for whom childbearing history (parity) was available. Twenty-six women were diagnosed with ARVD/C prior to or during at least one completed pregnancy and constituted our main study population. The remaining childbearing-aged patients with ARVD/C served as a comparison group. All registry enrolees provided informed consent. The study was approved by the respective institutional review boards.
Demographics, family history and cardiac characteristics were obtained by examination of medical records and patients’ self-report as per registry protocol (see online supplementary methods). Genotype was derived from direct sequencing of the desmosomal genes and the PLN gene through either our research17 ,18 or commercially available testing. ARVD/C diagnosis was established when 2010 TFC were fulfilled.
Cardiac events included: (1) sustained VA and (2) onset of heart failure (HF) ≥ Class C. Sustained VA was a composite measure of spontaneous sustained ventricular tachycardia (VT), aborted sudden cardiac death or appropriate implantable cardioverter defibrillator (ICD) intervention, as described previously.17 In women with multiple endpoints, the first event was considered the censoring event. Onset of Class C HF was defined based on modified guidelines of the American College of Cardiology/American Heart Association.19
Pregnancy course and outcomes
Cardiac and obstetric course were evaluated for each ARVD/C-affected pregnancy. Maternal phenotype was assessed at evaluation preceding pregnancy with ARVD/C, during pregnancy and at last follow-up. For this assessment, major structural RV abnormalities were considered those meeting major structural TFC based on review of echocardiography, cardiac MRI and RV angiography. Left ventricular (LV) dysfunction was defined as LV ejection fraction below 55%. Cardiac treatment prior to and during each pregnancy was recorded. Each pregnancy was evaluated for VA and HF, which were collectively considered major events. New or worsening ARVD/C-related symptoms were recorded.
The primary obstetric outcome was the rate of live-born children without health issues related to pregnancy and/or delivery. For each pregnancy, gestational duration, type of delivery, birth weight, obstetric complications and perinatal health were evaluated. Maternal and child health at last clinical follow-up were also assessed.
Comparison of major events in pregnant and non-pregnant women
Likelihood of VA, HF, cardiac transplant and death at last follow-up was compared between women who had and had not experienced pregnancy with ARVD/C. Incidence rates of VA and HF in the pregnant versus non-pregnant state were also compared.
Categorical variables were reported as frequency (%) and compared between groups by the χ2 or Fisher's exact test. Continuous variables were summarised as either mean±SD or median (IQR) and compared across groups using a t test, or Mann–Whitney U test as appropriate. Incidence rates of VA and HF were calculated as number of first VA and HF events per person-year in the pregnant versus non-pregnant state. Mid-P exact tests were used to compare incidence rates. A p value <0.05 was considered significant. SPSS (V.22; SPSS) statistical software was used.
The main study population included 26 women (21 American) who experienced at least one viable pregnancy (>13 weeks) while affected with ARVD/C. First pregnancies began a median 1.1 years (IQR 0.5–3.8) after diagnosis. Nearly half (12/26, 46%) received genetic counselling prior to at least one pregnancy. Table 1 shows clinical characteristics at first pregnancy.
These 26 women experienced 39 singleton pregnancies progressing beyond the first trimester (range 1–4, mean age 31.3±3.6) and 6 clinically recognised first trimester losses while affected with ARVD/C (table 2). The majority (n=29, 74%) of viable pregnancies began after ARVD/C was clinically recognised and treated, 7 (18%) began after the patient met TFC but ARVD/C was not yet clinically recognised and 3 (8%) pregnancies were ongoing at diagnosis. Sixteen (41%) pregnancies began in the setting of major structural RV abnormalities (n=7), history of VA (n=5) or both (n=4) and were considered potentially high risk. No pregnancy began in the setting of HF. An additional 18 pregnancies (0–4 per woman)—including three miscarriages—had been completed by these women prior to ARVD/C diagnosis without any major cardiac events.
Cardiac management and outcomes of ARVD/C pregnancies
Cardiac and obstetric course and medical management of each ARVD/C affected pregnancy are described in detail in table 2. Treatment during pregnancy included β blockers (n=16), antiarrhythmics (n=6), diuretics (n=3) and ICDs (n=28). ICDs were implanted during three pregnancies.
As summarised in figure 2, most pregnancies (n=32, 82%) were completed without major cardiac events (VA or HF). Among these pregnancies, nine involved new or worsening palpitations/premature ventricular complexes (n=7) and/or fatigue/dyspnoea (n=3). These symptoms were successfully treated via starting/increasing β blockers (n=3), adding flecainide (n=1) or short-term use of diuretics (n=1). In four symptomatic pregnancies (case 2—G2P1, case 17, case 24—G2P1 and G4P2), no medication adjustments were required.
Seven pregnancies were complicated by VA (n=5) or HF (n=2). As shown in table 3, the likelihood of a major cardiac event was not significantly increased in pregnancies begun in women with a prior history of VA and/or major structural RV abnormalities.
A single episode of VA complicated five pregnancies of five women without a prior history of sustained VAs. Interruption of β blockade was associated with two of these events.
Two VAs were terminated by appropriate ICD interventions. The first was an ICD discharge in the third week of a primigravida (case 6) who had increasingly frequent non-sustained VT prepregnancy. The second was a second trimester episode of anti-tachycardia pacing following a trial β blocker interruption. With restarted β blocker therapy this woman (case 9) completed this pregnancy without further VA and had three other uneventful pregnancies maintained on β blockers.
Three women experienced episodes of sustained VT prior to appropriate clinical recognition of their disease. Case 19 had a haemodynamically stable VT in week 12 of her second pregnancy. She was externally cardioverted, began metoprolol and received an ICD 3 days later. Case 21 had a haemodynamically unstable VT in the sixth week of her second pregnancy—2 weeks after discontinuing metoprolol. VT was terminated by cardioversion, sotalol 240 mg daily started and an ICD placed in week 22. Finally, a sustained VT in the sixth gestational week was the initial clinical presentation of a primigravida (case 25) subsequently treated with metoprolol 75 mg daily and ICD placement.
Overall, VA occurred more frequently in pregnancies of probands (5/21, 24%) than family members (0/18, 0%; p=0.05). Surprisingly, probands with no prepregnancy history of VA were most at risk (5/12 (42%) vs 0/9 (0%) probands with prepregnancy VA; p=0.045).
Two pregnancies of primagravidae were complicated by the onset of HF. Case 3 had a prepregnancy history of VA, major structural RV abnormalities and mild tricuspid insufficiency. She presented with dyspnoea and palpitations and was diagnosed with RV-predominant HF with severe tricuspid insufficiency in the fifth gestational month. She was successfully treated on an outpatient basis with diuretics and had an uncomplicated full-term vaginal delivery. During 2 years of follow-up, she was stable with partially improved tricuspid valve function.
Case 11 had overt biventricular disease prepregnancy (LV ejection fraction 30%–35%). Following recognition of pregnancy, she discontinued valsartan and was managed on metoprolol 25 mg daily. She developed dyspnoea, mild lower extremity oedema and increased fatigue in the fifth month and was diagnosed with biventricular HF with a decreasing LV ejection fraction (25%–30%) and mild-to-moderate pulmonary hypertension. Outpatient management was achieved with diuretics and digoxin. An uncomplicated caesarean section, indicated due to hemodynamic concerns, was performed at 39 weeks. With restart of valsartan and continued use of diuretics and digoxin, she is stable 5 years postpartum with unchanged LV function.
While HF was rare, it occurred in one of two pregnancies begun in the setting of LV dysfunction. In contrast, 9/10 (90%) pregnancies begun with major structural disease restricted to the RV were without HF.
All viable pregnancies progressing beyond the first trimester resulted in live-born children. Thirty-seven (95%) were delivered full term, and the other two preterm at 34 and 35 weeks. All were delivered in hospital. A total of 11 caesarean sections (28%) were performed: one exclusively for ARVD/C-related reasons (HF), the remainder for primarily obstetric indications. Minor obstetric complications (table 2) were noted in seven pregnancies (18%); no major obstetric complications occurred. As shown in table 3, birth weight was significantly lower (but normal) in pregnancies complicated by a major event (3.0±0.63 kg vs 3.5±0.57 kg no major events; p=0.047). This may be partly attributable to β blockade as birth weight was significantly lower in women taking β blockers beyond the eighth week (n=16) (3.1±0.48 kg vs 3.7±0.57 kg; p=0.002). There were no other differences in obstetric outcomes associated with major cardiac events during pregnancy. All children were alive and well at last follow-up at a median age of 3.4 years (IQR 1.6–6.8).
Association of ARVD/C course with pregnancy history
We explored whether experiencing pregnancy while affected with ARVD/C was associated with long-term disease course by comparing women who had pregnancies with ARVD/C with the remainder of our population of female childbearing-aged patients. As shown in table 4, at ARVD/C diagnosis there were no significant differences in clinical or demographic characteristics between women who later became pregnant and those who did not. After a mean 6.5±5.6 years of follow-up, there were likewise no significant differences in likelihood of having experienced a sustained VA or HF and no difference in likelihood of major RV structural dysfunction. All patients with ARVD/C who became pregnant were without cardiac mortality or transplant at last follow-up with none lost to follow-up. One woman died 1 year after her last delivery from breast cancer.
Incidence rate of VAs and HF in pregnant and non-pregnant women
Finally, to test whether incidence of VA and HF was more likely during pregnancy, we compared incidence rates of both in the pregnant and non-pregnant state. Among female patients with ARVD/C aged 15–45 years, the incidence rate of VA was 0.138 (CI 0.10 to 0.18) per non-pregnant person-year versus 0.274 (CI 0.10 to 0.61) per pregnant person-year (p=0.17). For HF, the observed incidence rates were 0.020 per person-year (CI 0.012 to 0.034) in non-pregnant versus 0.070 per person-year (CI 0.012 to 0.23) in pregnant state (p=0.16).
We investigated cardiac and obstetric outcomes of pregnant patients with ARVD/C ascertained from two large ARVD/C registries. Our study has four main findings. First, the majority of pregnancies were without major cardiac events. Sustained VA complicated 13% of pregnancies and HF 5%. Second, pregnancies resulted in live-born infants without major obstetric concerns and all children healthy at last follow-up. Third, at last follow-up, all pregnant patients with ARVD/C were without cardiac mortality or transplant and did not differ from other childbearing-aged patients with ARVD/C. Finally, the likelihood of experiencing a first sustained VA or developing HF was not significantly increased during pregnancy.
Prior reports of pregnancy in patients with ARVD/C
Only 13 pregnancies in patients with ARVD/C have been described in the literature, in contrast to far more robust populations for other inherited cardiomyopathies and arrhythmia syndromes.20 Bauce et al7 reported six Italian patients with mild-to-moderate ARVD/C who tolerated pregnancy well. Two authors described cases diagnosed during pregnancy who following ICD implantation and initiation of β blocker therapy delivered healthy infants.8 ,9 Güdücu et al10 describe an established ARVD/C patient with worsening symptoms during her second pregnancy due to β blocker interruption. In contrast, two primigravidae had full-term uncomplicated pregnancies while maintained on β blockers.11 ,12 Finally, Iriyama et al13 and Anouar et al14 each report an uneventful pregnancy with caesarean delivery in an established patient. The results of our study confirm and significantly extend these findings as we assessed cardiac and obstetric outcomes of sixfold more pregnancies than the largest prior report.7
Most ARVD/C pregnancies were without major cardiac events
We found most pregnancies, including those begun in the setting of major structural RV abnormalities and/or a history of sustained VAs, were free from major cardiac events. Isolated episodes of VA complicated five pregnancies of probands without prepregnancy VA history. The occurrence of four of these VAs in the first trimester might be related to an arrhythmogenic effect of hormonal changes at this time.21 ,22 Altogether, these results suggest fairly good arrhythmic outcomes when ARVD/C is well established and treatment adequate, particularly given the typical arrhythmic course of ARVD/C.6 HF developed in the second trimester of two women with pre-existing significant structural disease as hemodynamic load increased. Of note, HF did not develop in 90% of pregnancies begun with isolated RV abnormalities.
The reason for this favourable outcome is uncertain. In patients with ARVD/C, increased hemodynamic stress associated with exercise promotes arrhythmias and also negatively modifies cardiac structure.23 In contrast to exercise, the relatively shorter term and gradually developing nature of hemodynamic load during pregnancy might limit this process. In animal models, the myocardial response to volume- or pressure-induced stress is different in male and female hearts, with preserved ejection fraction and less fibrosis in female models. In addition, the interrelationship between oestrogen and testosterone may contribute to sex differences in disease manifestation.24 Similar mechanisms may also be protective in pregnancy.
Favourable obstetric outcomes
The obstetric course of patients with ARVD/C was largely unremarkable. All pregnancies resulted in healthy children without major obstetric complications. Both prematurity (6.5% of American subjects) and birth weights were normal,25 ,26 although women taking β blockers or experiencing major events during pregnancy had children with a significantly lower birth weight. First trimester losses represented a normal rate of 13% of clinically recognised pregnancies.27 Of 11 caesarean sections, only one was exclusively ARVD/C indicated (HF). The 28% caesarean-section rate was unremarkable, given the population rates of 33% in the USA and 17% in the Netherlands.28
No differences in long-term ARVD/C course and incidence of cardiac events
Among women of childbearing age with ARVD/C, the incidence rate of VA and HF was not significantly elevated during pregnancy. All pregnant patients with ARVD/C were without cardiac mortality or transplant at last follow-up. Furthermore, there was no difference in likelihood of sustained VA or HF at last follow-up between these mothers and women who had not experienced pregnancy with ARVD/C. This suggests that pregnancy does not lead to a precipitous decline in most women. Some caution while interpreting these data is warranted as pregnancy is, of course, not randomly selected.
Implications for clinical care
Our results suggest most patients with ARVD/C can be managed successfully through pregnancy and highlight several management considerations. Preconception arrhythmia management should be optimised using drugs with low fetal toxicity. ICD implantation, if indicated based on prepregnancy risk stratification,6 ,17 should be performed prior to pregnancy. Preconception assessment of biventricular structure and function is helpful since HF is more likely in those with structural abnormalities. LV dysfunction is associated with poor pregnancy outcomes in women with dilated cardiomyopathy20 and appears likely to be so for patients with ARVD/C as well. Genetic counselling to discuss the heritable nature of ARVD/C should be offered. Following recognition of pregnancy, discontinuation of medication with low fetal risk (eg, β blockers) is not advised. Vaginal delivery with cardiac monitoring is reasonable in many cases. For uneventful pregnancies, a 3-month postpartum visit followed by usual cardiac care is recommended as pregnancy is not expected to worsen long-term disease course.
Data were obtained from two registries; as such, management decisions were at the discretion of the treating physician and hence vary between pregnancies and between subjects. In particular, variability in evaluation of cardiac structure and function precluded definitive analysis of possible structural progression during pregnancy. While ARVD/C management is similar in America and the Netherlands,5 ,6 obstetric care differs substantially which may have influenced outcomes. However, while Dutch women have high rates of care by midwives, home-births, drug-free deliveries and relatively low caesarean section rates,28 the Dutch patients with ARVD/C had medically managed pregnancies with hospital deliveries.
Our study included no women with HF diagnosed prepregnancy, a population likely at very high risk. Ascertainment of subjects through a registry of living patients also creates a selection bias that may mask catastrophic pregnancy outcomes. With regard to comparison of long-term outcomes in the overall population, women obviously self-selected whether to become pregnant and hence may differ in some systematic way beyond the data shown in table 4. In particular, a subset of women may have been advised against pregnancy, but data on medical advice given regarding childbearing are unavailable.
We found most pregnancies in women with ARVD/C are tolerated well. Even most patients with a prior history of sustained VAs and isolated RV structural disease had favourable outcomes. However, β-blocker therapy was associated with lower birth weight and patients with pre-existing overt biventricular disease are likely at significant risk for developing HF as pregnancy progresses.
What is already known on this subject?
Only 13 pregnancies in women with arrhythmogenic right ventricular dysplasia/cardiomyopathy have been described in the literature in one small case series and seven case reports.
What might this study add?
We assess cardiac and obstetric outcomes of 39 pregnancies, triple the number previously reported. We also compare incidence of ventricular arrhythmias and heart failure in the pregnant and non-pregnant state, and long-term outcomes of childbearing-aged patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) who became pregnant with those who did not.
How might this impact on clinical practice?
This study significantly enhances the evidence base for patients with ARVD/C considering pregnancy and their physicians. These results suggest that most pregnancies of patients with ARVD/C are tolerated well. However, 13% of pregnancies were complicated by sustained ventricular arrhythmias and 5% by onset of heart failure.
The authors are grateful to the patients with ARVD/C who have made this work possible.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Contributors Each author meets the ICMJE recommended guidelines for authorship credit. There are quite a few authors as this study involved data collected over a decade in two countries. Each author revised the manuscript critically for important intellectual content and gave final approval of the version submitted. Each agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Specific contributions include: conception and design of the study: CAJ, JPvT, HC, SDR, MPvdB, KYvS-Z, DPJ and CT; acquisition and analysis of data: CAJ, ARH, ASJMtR, JAG, ACS, AAW, HT, DPJ, RNWH, HC, JPvT, CT and BM; interpretation of data: CAJ, ARH, ASJMtR, MPvdB, AAW, DPJ, SDR, RNWH, HC, JPvT, KYvS-Z, CT and BM; drafting the work: ARH, CAJ, JPvT and ASJMtR.
Funding The Johns Hopkins ARVD/C Program is supported by the Leyla Erkan Family Fund for ARVD Research, the Dr. Satish, Rupal and Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Dr. Francis P. Chiaramonte Private Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family, the Peter French Memorial Foundation and the Wilmerding Endowments. The authors also wish to acknowledge funding from the St. Jude Medical Foundation (investigator-initiated grant to HC, salary support for CAJ and CT). This work was performed during ASJMtR's tenure as the Mark Josephson and Hein Wellens Research Fellow of the Heart Rhythm Society. We acknowledge the support from the Netherlands Cardiovascular Research Initiative, the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences (AAW, MPvdB and JPvT).
Competing interests HC is a consultant for Medtronic, Inc. and St. Jude Medical and receives research funding from the St. Jude Medical Foundation and Boston Scientific Corp. CAJ and CT receive salary support from these grants.
Patient consent Obtained.
Ethics approval Johns Hopkins Medicine IRB, Ethics boards of University Medical Center Utrecht, University Medical Center Groningen and the Academic Medical Center—Amsterdam.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Details of ARVD/C Task Force Criteria are available from the corresponding author pending appropriate data use agreements.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.